| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |


From the Departments of Pathology
*
and Hematopathology,
The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and the Department of Pathology,
Geisinger Medical Center, Danville, Pennsylvania
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The t(14;18) translocation leads to the juxtaposition of the BCL2 gene (18q21) and the IgH locus (14q32). This IgH/BCL2 rearrangement results in overexpression of the BCL2 oncogene, which is thought to result in neoplasia by interfering with the normal apoptosis of B lymphocytes.1 On the BCL2 gene, 60% to 70% of breakpoints are clustered in the major breakpoint region (MBR) located in the 3' noncoding region, 20% to 30% occur in the minor cluster region (mcr) situated in the 3' flanking region, and the rest are widely scattered over the BCL2 genomic region.2 The breakpoints on chromosome 14 mostly lie in the joining region (J) on IgH.3, 4
Conventional cytogenetic analysis detects the t(14;18) translocation in only about 86% of FLs and requires fresh tissue and meticulous sample preparation.5 Molecular studies, including Southern blotting and polymerase chain reaction (PCR), fail to detect breakpoints outside the MBR and mcr regions, because of the dispersed breakpoints on both chromosomes. Alternatively, long-distance PCR amplification may detect an IgH/BCL2 rearrangement occurring within the approximately 30-kb region downstream from the MBR of BCL2, but this rather demanding technique is not available in many laboratories.6
Interphase fluorescence in situ hybridization (FISH) with specific genomic DNA probes for genes not only complements conventional cytogenetic, Southern blot, and PCR methods, it also can detect genomic aberrations at the level of individual cells. Therefore, it is a useful technique for detecting chromosome translocations. Two types of the interphase FISH approach are available for detecting the IgH/BCL2 gene. The first type is a segregation assay with probes for the BCL2 gene that will split in the case of a chromosomal breakpoint. However, the presence of segregation BCL2 signals is not direct proof of the t(14;18) translocation. For example, this type does not differentiate the t(14;18) translocation from polysomy 18 or from the t(2;18) or t(18;22) translocations.7 The second type is a colocalization base interphase FISH assay that uses specific probes for BCL2 and IgH. The IgH/BCL2 fusion is indicated directly by the touching or superimposed signals of two probes. Because this approach permits rapid screening of interphase nuclei and yields straightforward results, its use is preferable to segregation interphase analysis in clinical samples. However, the low detection efficiency of this second approach has made interpretation of results unreliable because the false-positive and false-negative rates have been high, mainly as a result of previous probe designs and the selection of DNA clones such as yeast artificial chromosome (YAC) and cosmid probes.8 In addition, the use of these clones requires more complicated DNA preparation methods. Thus, in a diagnostic setting, using these clones as probes severely reduces the practical value of the colocalization base interphase FISH assay. Furthermore, all previous FISH analyses of the IgH/BCL2 rearrangement have been performed on the metaphase and on cytogenetic preparations from peripheral, bone marrow, or tissue biopsy specimens. So far, no data are available on the application of FISH to cytologic specimens such as those obtained by FNA biopsy.
We reasoned that with the correct combination of probes, we should be able to overcome the problems with the colocalization base interphase FISH assay. To detect the IgH/BCL2 rearrangement simply and reliably, we have isolated by PCR and mapped by DNA fiber FISH assay bacterial artificial chromosome (BAC) clones that cover the entire BCL2 gene and the constant (C), J, and diversity (D) regions of the IgH locus. Using these probes, we designed and applied a colocalization base FISH assay to FNA biopsy specimens of lymph nodes from patients with and without FL. We validated the results by PCR analysis and DNA fiber FISH assay with the same probes.
| Materials and Methods |
|---|
|
|
|---|
|
Normal DNA fiber preparations were made as described previously.9 In brief, normal peripheral blood lymphocytes, at a concentration of 1 x 107 cells/ml, were embedded in 1% low-melting-point agarose (Promega, Madison, WI). Agarose blocks were incubated at 50°C in 2 mg/ml proteinase K for 48 hours, then washed in three changes of 1X 10 mM Tris-HCl/1 mM EDTA (TE) and treated with 100 µg/ml RNaseA in 2X 37.5 mM NaCl/3.75 mM sodium citrate (SSC) (Vysis, Downers Grove, IL). A small piece of the agarose-embedded DNA was placed on a microscope slide, and 14 µl of water was added. The DNA was extended mechanically on the slide by using the edge of another slide.
DNA fibers from the Cytospin preparations were made as follows: slides were fitted into plastic Cadenza chambers (Thermo Shandon, Inc., Pittsburgh, PA), and 150 µl of lysis solution (5 parts 70 mmol/L NaOH, 2 parts ethanol) was applied to the top of the chamber. The meniscus of the lysis solution was allowed to move down the slide. As the level droped below the frosted edge of the slide, 200 µl of ethanol was added and allowed to drain briefly. The slides were then fixed in Carnoys solution for 10 minutes.
Probes for FISH Assays
To obtain an appropriate BCL2 probe for FISH assay, we screened an 8X genomic-coverage BAC library (Research Genetics Inc., Huntsville, AL) with a PCR-based screening protocol with specific primers for exon II and mcr.10
The size of each BAC was estimated from agarose gels after enzyme digestion. The chromosomal location of the clones was confirmed on a normal metaphase spread in combination with a centromeric probe for chromosome 18 (CEP 18; Vysis, Downers Grove, IL). Mapping of the overlapping region of the BACs was performed on normal DNA fibers with dual-color labeling.11
Similarly, a BAC clone for IgH was isolated by PCR with human STS SHGC-11760 primer, and clone mapping was performed with specific primers for the C and J regions.11, 12, 13 The chromosomal location was confirmed using a normal metaphase spread in combination with a centromeric probe for chromosome 14 (CEP 14; Vysis). The size and mapping region of the BAC probe on IgH were analyzed on normal DNA fibers with a known 110-kb BAC clone (kindly provided by Mariano Rocchi, DAPEG Sezione di Genetica, Bari, Italy), which was mapped on the J and D regions.
FISH Assays
For FISH assays, the IgH probe was directly labeled by nick translation with SpectrumGreen-dUTP (Vysis), and the BCL2 probe was labeled with SpectrumOrange-dUTP (Vysis). One hundred nanograms of each probe was mixed with a 30-fold excess of human Cot-1 DNA (BRL-Life Technologies, Rockville, MD) in 10 µl of LSI hybridization buffer (Vysis), and mounted on a slide. Hybridization was performed using the HYBrite hybridization system (Vysis), and post-washing was performed as described previously.14
Interphase nuclei and DNA fibers were carefully examined using Leica microscopes equipped with appropriate filter sets for visualizing SpectrumGreen, SpectrumOrange, and DAPI counterstains (Leica Microsystems, Inc., Buffalo, NY). Images were captured using CytoVision (Applied Imaging Corporation, Santa Clara, CA).
PCR Analysis
PCR analysis was carried out to determine the presence of JH/BCL2 fusion DNA sequences consistent with the t(14;18) (q32;q21) translocation using the primers and methods described by Lee et al.15, 16
| Results |
|---|
|
|
|---|
|
|
For normal controls, we analyzed 200 consecutive nuclei per slide from the four lymph nodes without malignancy. Colocalized fusion signals were found in 0% to 5% of the cells (mean false positivity, 2%), whereas the positive IgH/BCL2 rearrangement cell line (WSU-NHL) showed that 76% of cells had at least one fusion signal. The cutoff value for positivity was determined to be 7% (mean ± 3 standard deviations). The same normal control specimens were analyzed by fiber FISH. At least 30 fibers were scored for the presence of the IgH/BCL2 rearrangement. Juxtaposition signals ranged from 0% to 3%. The cutoff value for positivity was fixed at 7%.
Detection of IgH/BCL2 Rearrangement by FISH in Patients
The IgH/BCL2 rearrangement was found in 24 of the 26 patients with FL (Table 1)
. In the positive samples, the percentage of cells with at least one IgH/BCL2 fusion was variable, ranging from 22% to 100% (mean, 63%), statistically significantly higher than the 7% cutoff value. Although the percentage of cells with fusion of two probes in the FL-negative samples ranged from 1% to 5%, this range was significantly lower than that observed for FL-positive cases; however, no significant difference occurred between this range and that of the normal controls (Table 1)
.
In all 24 positive cases detected by interphase FISH, the IgH/BCL2 rearrangement was confirmed by fiber FISH with the same probes, and the abnormality occurred in 10% to 79%. The two cases that were negative for the rearrangement by interphase FISH were also negative by fiber FISH, although 36% of the cells in one of the two cases showed two IgH signals and multiple BCL2 signals. A dual-color FISH analysis of the case with the CEP 18 and BCL2 BAC probes always showed two signals of the CEP 18 per cell, which excludes the possibility that multiple BCL2 signals were simply a result of aneuploidy of the entire chromosome 18 in the cases.
Comparison of FISH Assay and PCR Analyses
Among the 24 FL-positive cases detected by both FISH techniques, 19 were also positive by PCR analysis. The two cases that were negative by the FISH techniques also were negative by PCR. Only two of the FL-negative samples were tested by PCR, and they were negative for the IgH/BCL2 rearrangement (Table 1)
.
| Discussion |
|---|
|
|
|---|
Our new set of DNA probes rapidly and reliably detected the IgH/BCL2 rearrangement in 92% of the specimens from patients with FL without false positivity in the normal controls or the FL-negative specimens. This 92% positivity demonstrated a high level of diagnostic sensitivity of this set of probes in cytologic preparations from FL; the sensitivity of the probes in interphase was confirmed by fiber FISH. Our results suggest that these new probes are particularly advantageous for use with cytologic specimens that have limited cellularity and contain desegregated cells.
The colocalization base interphase FISH approach was previously reported to have a low detection efficiency because of highly variable false-positive rates in normal nuclei and false-negative rate in positive cells.17 It is extremely difficult to distinguish positive cases from normal samples when the percentage of cells with fusion signals is close to the cutoff value, particularly in tumor specimens that have a large number of normal cells. The false-positive rate may be ascribed mainly to unstable and chimeric YAC clone DNA because the YAC clones contain unstable and chimeric DNA sequences, which often yield diffuse, nonspecific signals.18, 19, 20 In addition, detection of the YAC probe requires an antibody immunostaining technique; this strategy also increases nonspecific signals. Therefore, YAC signals are scored ambiguously and the rates of false fusion and coincidental colocalization signals are high, further yielding a high average rate of false-positive nuclei, especially in the interphase.21 On the other hand, the false-negative rate may frequently result from probes that consist of a pool of YAC and a small clone, such as a phage or cosmid, because these clones cover only partial regions of genes and have genomic gaps. In this case, some complex rearrangements, such as excision of the BCL2 gene from chromosome 18 and insertion into the IgH locus and breakpoints that locate very telomerically on one gene and very centromerically on another gene, would be undetected by one 5' probe and one 3' probe of BCL2 or IgH.22 This is especially true when the cells are in the S/G2 phases of the cell cycle. Furthermore, the physical distance of the two probes within fusion signals may vary widely as the sizes of the cells and nuclei and the location of the breakpoints change. Therefore, if there are gaps in both probes, it will be very difficult to fix a cutoff distance for determining whether signals are fused or separated. This would lead to high inter-observer variability making the interpretation of the results even more difficult.4, 17, 23
We set out to develop new sets of probes by using BAC clones. The insert of the BAC clone has high genomic coverage and is 80 to 300 kb long, which is several times longer than that in a cosmid or phage (10 to 30 kb), and therefore provides relatively efficient analysis data.24 We labeled the DNA directly without amplifying human DNA using Alu-PCR because the BAC clone contains a highly stable and rich human genomic insert. This set of BAC clones always results in clear, sharp, bright spots on monolayer cytologic preparations. In addition, the probes were produced by the direct incorporation of fluorochrome-labeled nucleotides that eliminate the need for immunostaining to amplify the signals, thereby reducing nonspecific hybridization. In normal controls, the probes have a low cutoff value and show a significantly low percentage of false-positive IgH/BCL2 fusion cells in FL-negative samples, effectively eliminating false positivity.
As shown with normal DNA fibers, two BAC clones of the BCL2 probe have a minimal overlap of 50 kb, covering the entire gene from upstream of 3' to downstream of 5'. The IgH BAC probe spans the C, J, and D regions of the locus. There are no sequence gaps in the probes, effectively eliminating the possibility of false negatives. Because breakpoints always occur in the J region of IgH in FL whenever t(14;18) involves the IgH/BCL2 rearrangement, breakage of the BCL2 is demonstrated by fusion of the different labeled probes on chromosome 14,18 or both. In this study, the probes were designed to eliminate the false-positive rate. Only the touching or overlapping of two different color probes was considered to be a fusion signal, and this was confirmed by the close connection of two different color barcode signals in a single DNA fiber on the same cases. According to this criterion, an elevated percentage of nuclei with at least one fusion signal was demonstrated in 24 of the 26 FL cases (mean, 63%). In contrast, no FL-negative sample contained more than 5% of nuclei with fusion signals. This difference in the percentage of fusion signals between FL-positive and FL-negative cases was statistically significant.
PCR analysis detected the IgH/BCL2 rearrangement in 19 of 26 cases of FL. Even though it can confirm a cytologic diagnosis of lymphoma in FNA specimens, PCR is of limited value in the diagnosis of FL without morphological or clinical support because of its high rate of false negativity.25 Compared with PCR analysis, the dual-color colocalization base FISH assay with our set of probes is much more sensitive (92 vs. 73%) for detecting IgH/BCL2 rearrangement in cytologic specimens.
Two documented FL-positive cases were negative for IgH/BCL2 fusion by both FISH and PCR analyses. It is interesting to note, however, that 36% of cells in one of the two samples demonstrated multiple BCL2 signals by FISH, suggesting a split, amplification, or rearrangement of the BCL2 gene and resulting in overexpression of the BCL2 oncogene. This probably indicates that the transformation of FL cells in this case was not associated with a chromosomal translocation involving IgH but instead was associated with another chromosomal locus or mechanism, such as mutations of the BCL2 gene. This might cause increased expression of BCL2 by affecting the interactions of BCL2 with other proteins.26, 27, 28 However, with our unique probes, we could still detect the genomic rearrangement of the BCL2 gene.
Recently, using a commercial set of probes (Vysis), Frater et al 29 detected t(14; 18) (q32; q21) translocation in 25 of 39 FL cases. Their sensitivity (64%) is the lowest in all reported studies using FISH to detect t(14;18) and is even lower than that in the studies using PCR and conventional cytogenetic methods.4, 8, 21, 23, 29 The practical value of the commercial probes needs to be validated in further well-designed studies, especially in terms of sensitivity, specificity, and cutoff value. Our new set of probes is more convenient and more sensitive than those previously used to detect the IgH/BCL2 fusion. Our colocalization base FISH assay can be a useful adjunct in diagnosing FLs, especially on small samples such as those obtained by FNA biopsy. Thus, these small samples can be accurately classified which will aid in predicting the biological and clinical behavior of the disease.
| Acknowledgments |
|---|
| Footnotes |
|---|
Supported by National Institutes of Health grant RFP N01 CN 85083 57 (to R.L.K), Developmental Project/Career Development Award from the University of Texas Specialized Programs of Research Excellence (SPORE) in Lung Cancer (P50 CA70907) (to F.J.), and the W. M. Keck Center for Cancer Gene Therapy Award (to F.J.).
Accepted for publication June 4, 2002.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Li, N. W. Todd, Q. Qiu, T. Fan, R. Y. Zhao, W. H. Rodgers, H.-B. Fang, R. L. Katz, S. A. Stass, and F. Jiang Genetic Deletions in Sputum as Diagnostic Markers for Early Detection of Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., January 15, 2007; 13(2): 482 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Z. Rassidakis, R. Lai, M. Herling, C. Cromwell, A. Schmitt-Graeff, and L. J. Medeiros Retinoblastoma Protein Is Frequently Absent or Phosphorylated in Anaplastic Large-Cell Lymphoma Am. J. Pathol., June 1, 2004; 164(6): 2259 - 2267. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Braziel, M. A. Shipp, A. L. Feldman, V. Espina, M. Winters, E. S. Jaffe, E. F. Petricoin III, and L. A. Liotta Molecular Diagnostics Hematology, January 1, 2003; 2003(1): 279 - 293. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |